Subject(s)

Agammaglobulinaemia Tyrosine Kinase , Central Nervous System Neoplasms , Immunotherapy, Adoptive , Lymphoma, Mantle-Cell , Protein Kinase Inhibitors , Humans , Immunotherapy, Adoptive/methods , Immunotherapy, Adoptive/adverse effects , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/therapy , Lymphoma, Mantle-Cell/pathology , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Central Nervous System Neoplasms/therapy , Central Nervous System Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Protein Kinase Inhibitors/adverse effects , Treatment Outcome , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Aged , Receptors, Chimeric Antigen , Female , Combined Modality Therapy

Subject(s)

Lymphoma, Mantle-Cell , Humans , Adult , Lymphoma, Mantle-Cell/drug therapy , Tumor Microenvironment , Protein-Tyrosine Kinases , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use